Dr. George Han discusses new and upcoming systemic agents for the treatment of psoriasis from the resident's perspective, including novel biologics and small-molecule drugs. He explains how these new treatments work. Familiarity with these medications and their mechanisms of action will help dermatologists decide what the best treatment strategy is for each patient.
Dr. Jashin Wu discusses combination therapy with tumor necrosis factor inhibitors for psoriasis.
Pediatric psoriasis is an autoimmune diathesis with a complex immunologic basis. It is associated with extensive psychological morbidity and...
The passage of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) allowed for the creation of a regulatory pathway for new,...
The concept of unmet needs in psoriasis is not new. We are aware that both patients and physicians feel there are gaps in the management and...
It is well established that increased body mass index and weight gain are risk factors for psoriasis, and the prevalence of obesity in patients...
